根据弗若斯特沙利文数据分析，全球寡核苷酸药物市场规模从2016年0.1亿美元增长至2021年32.5亿美元，年复合增长率高达217.8%。根据Evaluate和BCG分析，2026年全球寡核苷酸市场规模将达到150亿美元（约合人民币1067亿元）。

In the trial, doses ranging from 0.5mg to 0.9mg of ALG-055009 led to notable median relative reductions in liver fat.

Several ASX companies are conducting clinical trials, and this has become a valuable sector and an asset to the Australian ...

Sarepta's Elevidys approval, revenue growth projections, and competitive position make it a strong investment in DMD ...

AstraZeneca's take on the PCSK9 inhibitor – an antisense drug licensed from Ionis six years ago – has cleared a proof-of-concept trial in high-risk patients with high blood cholesterol ...

Increased funding and new public health policies for sickle cell research are needed to ease the burden on low-income nations ...

Here we report the use of C5-propynyl-dU,dC-phosphorothioate antisense oligonucleotides to inhibit IGF-I receptor expression in keratinocytes. We identified several inhibitory antisense ...

Clinical decision-making can be difficult for patients with SMA due to the lack of clinical trials comparing treatment ...

AcuraStem has received $4 million in funding from the California Institute for Regenerative Medicine (CIRM) to advance the ...

ASX health stocks have fallen this week but Morgans analyst Scott Power is more optimistic after the Fed cut the cash rate by ...